Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601863 | 0.86 | QRFPR (0.52) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL4393554 | 0.79 | QRFPR (0.60) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7602137 | 0.79 | QRFPR (0.51) | QRFPRNOS1CYP2D6NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL4406109 | 0.78 | QRFPR (0.59) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7564087 | 0.78 | QRFPR (0.66) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7569688 | 0.78 | QRFPR (0.65) | QRFPRNOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL7563787 | 0.77 | QRFPR (0.64) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7562858 | 0.77 | QRFPR (0.71) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7970405 | 0.76 | QRFPR (0.63) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7564262 | 0.75 | QRFPR (0.56) | QRFPRNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | claimed |
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | QRFPR 1733/4885NOS1 7/4885CYP2D6 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.